You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
SBC: VASADE BIOSCIENCES, INC. Topic: NIAProject Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative stress and mitochondrial dysfunction correlate with the development of beta-amyloid (Aβ) deposits, one of the hallmarks of AD that begin years before the onset of memory and cognitive decline. Moreove ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Next-generation nanomedicine for acute ischemic stroke
SBC: Nanomuse, LLC Topic: NINDSABSTRACT / PROJECT SUMMARYAcute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trial ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups
SBC: JP LABORATORIES INC Topic: 300Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B
SBC: NECTAGEN INC Topic: NIAIDInfection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.
SBC: Zena Therapeutics Inc. Topic: NIDAOpioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
SBC: Prokaryotics, Inc. Topic: NIAIDWidespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Recombinant E-NTPDase for shock
SBC: Purine Pharmaceuticals Inc. Topic: 300SUMMARYInflammation after ischemia and reperfusion injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incident scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re-initiation of blood flow causes activation of several inflammatory mediators, suc ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
SBC: YAYA SCIENTIFIC LLC Topic: NIBIBPROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
STARTUP Central
SBC: CONTINUUM EDUCATIONAL TECHNOLOGIES, PBC Topic: 500PROJECT SUMMARY Continuum Educational Technologies’ (Continuum) will work with the University of Kansas (KU) on the proposed I-RED program entitled Smart Tools to Accelerate Research Translation by Uplifting Participants for the Central IDeA State Region (STARTUP Central) program to stimulate technological innovation in the IDeA state regions by addressing the entrepreneurial educational needs o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.
SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC Topic: NIAAbstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health